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 INTRODUCTION 
 
Electro convulsive therapy (ECT) is a treatment that has generated 
considerable controversy since its introduction to psychiatric practice in 
1938.    However a series of well conducted studies since the 1970s have 
conclusively established the efficiency of ECT in the treatment of 
affective disorders especially depression and to a lesser extent in the 
treatment of schizophrenia.  Modifications of ECT practice over the last 
four decades have considerably improved its safety and efficacy. 
     Ever since “Modified electroconvulsive therapy”is introduced in 
1963, by the use of Intravenous anaesthetic agents, neuro muscular 
blockade and assisted or controlled ventilation with oxygen, the 
ANAESTHESIOLOGIST has a significant role to play in this modality of 
treatment in psychiatry. 
The Anaesthetic requirements for ECT are 
1. Amnesia 
2. Airway Management 
3. Prevention of bodily injuries 
4. Attaining haemodynamic stability 
5. Smooth and rapid emergence 
 Anaesthesiologists must be equipped with an in-depth 
understanding of the changes affecting cardio vascular system, 
respiratory system and central nervous system by the treatment process 
and the pharmacological measures to attenuate them. 
As the treatment process of ‘Modified electroconvulsive therapy’ is 
associated with significant haemodynamic disturbances, the 
Anaesthesiologist should reacquaint with relevant aspects of electro 
convulsive therapy, understand the effects of anaesthetic agents on the 
effectiveness of electroconvulsive therapy with an aim to acquire 
technical skill in this segment of Anaesthetic practice. 
 Electro convulsive therapy under general anaesthesia is associated 
with transient but significant hypertension and tachycardia.  
Cardiovascular derangements are due to lability of arterial blood pressure 
resulting in systemic complications in the susceptible patients with 
myocardial infarction, congestive cardiac failure and cerebrovascular 
accident.  Haemodynamic lability is due to parasympathetic and 
sympathetic stimulation and adrenomedullary catecholamine release. 
 In clinical practice many different strategies have been advocated 
for modification of cardiovascular changes like administering beta 
blockers, calcium channel blockers, Lignocaine and fentanyl. 
  Use of different induction agent is one such strategy employed to 
obtund the cardiovascular response to ECT. 
An ideal Anaesthetic agent for ECT should provide a smooth rapid 
induction, a rapid recovery and attenuation of the physiological effects of 
seizure activity. 
Many centres in India use Thiopentone sodium which is an ultra 
short acting barbiturate. Now many other drugs like methohexitone, 
midazolam, etomidate and propofol were used as alternative induction 
agents. 
In my study, I have compared thiopentone sodium and propofol as 
induction agents for modified electroconvulsive therapy. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
AIM OF THE STUDY 
 
 To compare the induction agents, thiopentone sodium and 
propofol  with regard to 
a) Haemodynamic changes 
b) Seizure duration 
c) Recovery from anesthesia 
d) Clinical outcome 
In patients undergoing modified electroconvulsive therapy (MECT) 
for treatment of depression or mania. 
 
 
 
 
 
 HISTORY 
 
Ladislas Meduna , a Hungarian Neuropsychiatrist  and 
pathologist, in 1934 successfully treated a catatonic man by pentylene 
tetrazol   (Metrazol) which induced epileptic fits. 
Convulsive therapy was induced by insulin (Sakee) and with the 
inhalant Hexafluorodiethyl ether. 
Electrically induced seizures, introduced by Cerelitti and Bini 
(1938) are the only form of convulsive therapy currently employed 
worldover. 
In 1940, Bennett described the use of Curare for modifying drug 
induced convulsions and not electroconvulsions.  Curare was 
subsequently used in electroconvulsive therapy. 
During this period Bellett in 1941, Kolb in 1946 and Altschute in 
1947 with their associates reported cardiovascular complications after 
convulsions. Further advances in modification of convulsion during ECT 
came with the introduction of gallamine by Hughenard and Bone in 1949 
and introduction of succinylcholine by Holmberg and Thesieff in 1951. 
Reports on the use of these drugs in electroconvulsive therapy 
preceded papers on their use in General Anaesthesia . 
 In 1959, Friedman reported the use on intravenous methohexital for 
modification of seizure activity. 
By 1960’s the technique of using short acting intravenous 
barbiturates and depolarizing muscle relaxants became accepted as 
simple, safe regime in order to produce modified eletroconvulsive 
therapy. 
The early electroconvulsive therapy treatments were “Unmodified” 
i.e., neither implemented by sedation, anaesthesia, neuromuscular 
blockade nor by supplementary oxygenation and ventilation. 
Beginning in 1963, the treatment was ‘MODIFIED’ by the use of 
intravenous anaesthetic agents, neuromuscular blockade, and assisted or 
controlled ventilation with 100% Oxygen.  This gradually became the 
practice in most of the countries. 
 
 
 
 
 
 
 
 INDICATIONS FOR ECT 
 The primary indications of ECT are 
a) Where a need exists for rapid, definitive response on either medical 
or psychiatric grounds,  
b) When the risk of other treatments outweighs the risks of ECT  
c) When a history of poor drug response and / or good ECT response 
exists for previous episodes of illness  
d) The diagnostic conditions where ECT has been shown to be useful 
are : 
I.  DEPRESSIVE DISORDERS  
 People with unipolar and bipolar depressions show a 70% response 
to ECT. People given ECT to treat depression show a faster response than 
with antidepressants alone. ECT is indicated in depressed people with a 
high suicidal risk, who are in stupor, drug non-responders or partial 
responders, and are noncompliant.  Depressed people with biological 
disturbances or psychomotor retardation or psychotic symptoms show the 
best response to ECT. Continuation therapy with antidepressants / lithium 
is required to prevent relapses after treatment with ECT. 
 
 
 II - MANIA 
 ECT combined with antipsychotics results in faster recovery than 
with antipsychotics or lithium alone.  More frequent treatments are 
possibly associated with faster recovery than less frequent treatments. 
People with mania with severe disturbances show good response to ECT. 
III – SCHIZOPHRENIA  
 ECT combined with antipsychotics produces a faster recovery from 
relapses in the first 6 weeks of treatment than antipsychotics alone, 
though this advantage is not always maintained over the long term. ECT 
may be of benefit in some people with schizophrenia who show a limited 
response to antipsychotics.  When ECT is given with antipsychotics, an 
adequate clinical response is usually seen within 12 treatments, though in 
some instances, up to 20 treatments may be necessary. Patients with 
depressive, catatonic symptoms show good response with ECT, while 
people with chronic illness characterized by prominent negative 
symptoms may respond only minimally or not at all. 
IV - SCHIZOAFFECTIVE DISORDERS 
 Evidence from retrospective studies shows that ECT may be useful 
in the treatment of acute episodes. 
 
 V – OTHER FUNCTIONAL PSYCHOSES 
 Acute psychoses usually respond well to antipsychotic medication 
which is the treatment of choice, but ECT is also effective, if otherwise 
indicated. 
VI – SECONDARY DEPRESSION 
 Depression secondary to obsessive – compulsive disorder, severe 
anxiety states and reactive depressions, particularly if significant 
biological disturbances, psychomotor retardation and/ or psychotic 
features are present, may be given ECT if required.  
 
 
 
 
 
 
 
 
 
 
 
 CONTRAINDICATIONS FOR ECT 
 
ABSOLUTE: Recent Myocardial Infarction 
   Recent Cerebrovascular accident 
   Intracranial mass lesion 
   Phaeochromocytoma 
RELATIVE: Angina pectoris 
   Congestive heart failure  
   Severe pulmonary disease 
   Severe osteoporosis 
   Major bone fractures 
   Glaucoma 
   Retinal detachment  
   Pregnancy 
   Thrombophlebitis 
 
 
 
 
 
 METHOD OF ADMINISTRATION OF ELECTROCONVULSIVE 
THERAPY 
 
 ECT is administered by a ECT machine. The waveform, frequency 
and duration of the electrical stimuli from ECT machine can be adjusted 
through a wide range to produce the type of generalized seizure intended. 
Current instruments are brief pulse instruments that use lower dosage of 
electrical energy. It involves flow of electrical energy only during each 
pulse duration, which is brief and of square wave form (MMECTA – 
Multiple Monitored Ect Apparatus / machine). A two channel chart 
recorder for EEG and ECG allows monitoring of the presence and 
duration of seizure activity as well as cardiac activity. In bilateral ECT, 
an electrode is placed over each hemisphere whereas in unilateral ECT, 
both electrodes are placed over one hemisphere. 
NUMBER OF TREATMENTS 
Usually a treatment schedule of six to eight ECT sessions spread 
over a period of two weeks. One or two day interval is left between two 
sessions. In resistant cases, maintenance ECT is also carried out. 
 
 
 
 MECHANISM OF ACTION 
Generalised electrically induced seizures of the central nervous 
system are the sine qua non for the therapeutic effects of 
electroconvulsive therapy. 
The psychological mechanism responsible for the therapeutic effect 
remains largely unknown. 
EXPLANATIONS OFFERED FOR THE THERAPEUTIC EFFECT  
a)   NEUROPHYSIOLOGICAL ALTERATIONS IN  
Permeability of Blood Brain Barrier 
Cerebral microcirculation 
Neurometabolic activity  
Brain electrical activity 
b)   NEUROENDOCRINOLOGICAL 
Acute neuroendocrine discharge of ACTH, prolactin and 
hypothalamic peptides. 
c)   NEUROCHEMICAL CHANGES IN  
Ion transport systems  
Brain neurotransmitter receptor systems 
Biogenic amines 
d) BETA ADRENERGIC RECEPTOR STIMULATION MECHANISMS  
e)  ELECTROLYTE CHANGES  
 PHYSIOLOGICAL EFFECTS OF ELECTROCONVULSIVE 
THERAPY 
 
The physiological effects of electroconvulsive therapy can be 
classified under the following headings. 
 
1. CARDIOVASCULAR EFFECTS 
 
2.  CEREBROVASCULAR CHANGES 
 
3. NEUROENDOCRINE RESPONSES 
 
4.  SEIZURE RESPONSE 
 
5.  ENDOCRINE RESPONSE 
 
6. ENZYME CHANGES 
 
7. MISCELLANEOUS EFFECTS 
 
The diagram alongside illustrates the physiological events 
following administration of the electroshock. 
The following table gives the physiological consequences of 
electroconvulsive therapy. 
 
 
 
 
 TABLE ILLUSTRATING THE PHYSIOLOGICAL CONSEQUENCES OF 
ELECTROCONVULSIVE THERAPY 
 
CARDIOVASCULAR EFFECTS 
          Immediate: parasympathetic stimulation* 
           Bradycardia  
           Hypotension  
            Asystole (possible) 
           Late (after 1 minute): sympathetic stimulation** 
           Tachycardia  
           Hypertension 
           Arrhythmias  
Cardiac output 
Myocardial oxygen consumption 
CEREBRAL EFFECTS 
¾        Cerebral oxygen consumption (CMRO2) 
¾        Cerebral blood flow (CBF) 
¾        Intracranial pressure (ICP) 
MISCELLANEOUS EFFECTS 
      Intragastric pressure  
      Intraocular pressure 
 
 
*   Occurs immediately after passage of current  
** Occurs within minutes. 
 
 
 
 CARDIOVASCULAR EFFECTS 
            Cardiovascular changes may be the most important and dangerous 
complications of ECT.  They are more common in elderly patients and 
patients with co-existing cardiovascular disease.  
 The typical cardiovascular response to ECT consists of generalized 
autonomic nervous system stimulation with an initial parasympathetic 
induced bradycardia lasting 10 to 15 seconds followed immediately by a 
more prominent sympathetic response that is associated with the release 
of catecholamines and occasionally cardiac arrhythmias. 
Arrhythmias during the parasympathetic phase can include several 
seconds of asystole, bradycardia, premature ventricular contraction 
(PVC), or ventricular escape. Other sign of increased vagal tone (eg. 
Hypotension) may be present. 
During the subsequent sympathetic stimulation and clonic muscle 
phase, the increase in circulating catecholamine is directly related to the 
current intensity. 
The most frequent arrhythmias are sinus tachycardia, ventricular 
tachycardia and premature ventricular contractions (PVC).  Sinus 
tachycardia can vary from 20 to 115 percent of the preshock heart rate; 
peaks approximately 2 minutes post shock, and is usually self-limited.   
  Systolic and diastolic blood pressures are increased by 30-40 
percent.  There is a two to four fold increase in the rate pressure product 
(RPP) an index of myocardial oxygen consumption. Arterial blood 
pressure, heart rate and arrhythmias decline in parallel with the fall in 
plasma catecholamine levels.  Occasionally arrhythmias and hypertension 
can persist.  Whole body and myocardial oxygen consumption rates 
increase during ECT and venous return is decreased during the 
convulsion.  The clinical significance of these changes in oxygen 
consumption and cardiovascular function will depend on the patient’s 
general condition.  This rise in circulating catecholamine can be blunted 
by anaesthesia. 
CEREBROVASCULAR CHANGES: 
Cerebrovascular changes include a brief period of vasoconstriction 
when the electrical stimulus is applied, followed by a sustained increase 
in cerebral metabolism and blood flow.  The increase in cerebral blood 
flow can result in an increase in intracranial volume and intracranial 
pressure which is of concern in patients with intracranial mass lesions, 
increased intracranial pressure from any cause or cerebrovascular 
anomalies. 
 
 NEUROENDOCRINE RESPONSES: 
Electroconvulsive therapy activates noradrenergic systems, 
enhances dopamine receptor sensitivity and reduces serotonin uptake. 
ECT activates the peripheral autonomic nervous system and causes 
release of secretions from many endocrine glands. 
NEUROENDOCRINE RESPONSES TO ECT  
1. An immediate release of ACTH with peak plasma levels at 2 to 5 
minutes, which returns to normal by 45 minutes. 
2. An increase in PLASMA CORTISOL, level with peak at 30 
minutes, returns to normal in 2 to 4 hours 
3.  An increase in PLASMA EPINEPHRINE  concentration to 15 
time baseline by 1 minute, which returns to normal at 10 minutes. 
4. An increase in PLASMA NOREPINEPHRINE level to three time 
baseline at 1 minute, which returns to normal by 20 minutes. 
5. Transient increased release of glucagons and inhibition of glucose-
mediated insulin secretion. 
SEIZURE RESPONSE 
The waveform, frequency and duration of the electrical stimulus 
from the ECT machine can be adjusted through a wide range to produce 
the type of generalized seizure intended.   
 Preceded by a latent period of 2-3 seconds, a bilateral grandmal 
convulsion ensues, a tonic phase of 10-20 seconds followed by a clonic 
phase of 30-50 seconds. 
 Reducing the duration of convulsion activity would result in 
the reduction of therapeutic effect as shown by the various studies. 
The threshold has been clinically lower in males than in females, 
and lower in younger than elderly patients. 
ENDOCRINE RESPONSES: 
The therapeutic efficacy of electroshock has been ascribed to a 
variety of endocrine changes occurring during therapy, most of which 
have no clinical side effects. 
The notable exception is the effects of ECT on Diabetes mellitus. 
In the diabetic patient,electrically induced seizures produce elevations of 
a rapid order of circulating catecholamines and cortisol, a transient rise in 
glucagon levels, and inhibition of glucose-mediated insulin secretion. 
All of these effects can result in a relative hyperglycaemia in the 
diabetic patient.  Since ECT appears to cause a variable effect on glucose 
levels in diabetic patients, vigilance in the medical management of the 
diabetic patient during a series of ECT treatment sessions is necessary.  
Blood glucose levels of all diabetic patients requiring ECT should be 
 carefully monitored during the series and for as long as 3 weeks after 
termination of the treatment. 
ENZYME CHANGES 
Although cardiac complications have been frequently implicated in 
the morbidity and mortality, ECT per se does not appear to be involved in 
direct cardiac tissue damage.   
Following ECT, The total CPK concentration frequently increases, 
with the highest values at 6 hours, and returns to normal values by 48 
hours.  However there is no elevation of the isoenzyme CPK-MB which 
indicates myocardial damage.  There is no elevation of LDH 1 and LDH2 
and serum glutamate transaminases. 
MISCELLANEOUS EFFECTS: 
Electroconvulsive therapy produces significant elevations in 
intraocular pressure subsequent to the onset of the seizure.  Elevated 
intragastric pressure is also an inevitable accompanying effect of the 
convulsion. 
 
 
 
 
 COMPLICATIONS OF ECT 
 
 Fear and anxiety at induction 
 Muscle aches and headache  
 Memory disturbances – Anterograde and Retrograde 
 Damage to teeth, tongue, eyes, cutaneous structures 
 Prolonged seizures  
 Pulmonary aspiration 
 Laryngospasm 
 Prolonged apnoea 
 
CARDIAC COMPLICATIONS 
These form the main reason for mortality in electroconvulsive 
therapy. Cardiovascular mortality has been reported to be 0.03%. The 
complications include Atrial arrythmias, AV dissociation, ST segment 
depression and a variety of changes and these have been discussed 
elaborately in the section on physiological effects of ECT. 
 
 
 
       PRINCIPLES OF ANAESTHETIC MANAGEMENT  
 
General anaesthesia for electroconvulsive therapy is intended to 
provide the patient with lack of awareness of the electrical treatment, 
modification of the motor effects of the seizure in order to prevent injury, 
rapid recovery and minimal side effects and compatibility with 
medications the patient is taking. 
Brief general anaesthesia has added to the safety and comfort of 
modified electroconvulsive therapy.  While a simple procedure, there are 
several areas in which ECT differs from other procedures requiring brief 
anaesthesia.  These differences call for even more collaboration, 
interaction and cooperation between an anaesthesiologist and psychiatrist 
than is customary. 
Though the technical aspects of anaesthesia for electroconvulsive 
therapy seem straight forward and are of relatively minor complexity in 
an anaesthesiologist’s overall practice, there are four areas which should 
command particular attention from anaesthesiologists. 
First, while only a short time period is involved in modified 
electroconvulsive therapy when compared to other medical procedures 
requiring brief anaesthesia. 
 Secondly, both the physiological and pathological aspects of the 
anaesthetic process itself may influence the actual treatment outcome. 
Thirdly, because of the possible effect of anaesthesia on 
electroconvulsive therapy and the relative brevity of the treatment itself, 
more preliminary and on-the-spot coordination between anaesthesiologist 
and psychiatrist is necessary. 
Fourth since the procedure is repetitive, an optimum anaesthetic 
regimen can be sought for each patient. 
Anaesthetic requirements for successful modified electroconvulsive 
therapy are fourfold. 
• Rapid and smooth induction 
• Attenuation of the physiological effects of ECT 
• Rapid recovery after the seizure 
• Minimization of any antagonistic effects on seizure 
activity by anaesthetic agents. 
 
 
 
 
 
 ASSESSMENT OF PATIENTS FOR ANAESTHESIA BEFORE ECT 
 
All patients subjected to ECT should undergo a thorough physical 
examination and a detailed medical history should be taken.  Particular 
attention should be paid to cardiorespiratory function, allergies and 
previous anesthetic experience and a full neurological assessment should 
be made.  The presence or absence of loose or missing teeth should be 
recorded.  The patient should give written consent to the procedure. 
Minimum Investigation that are done 
  Haemoglobin 
 - Urine          -   Alb 
    -   Sugar 
 - Blood  - Urea 
    - Sugar 
    - Creatinine 
 - Chest X ray 
Other tests should be performed if clinically indicated.   
Records should be kept for each administration. This should 
include details of the drugs given and their effects, the nature and 
duration of the convulsion, the heart rate and blood pressure during the 
treatment and subsequent 60 minutes and any side effects or 
complications encountered. 
  
PREANAESTHETIC PREPARATION 
 
The immediate preanaesthetic preparation of the patients, as for any 
anaesthetic, must include a period of fasting of at least 6 hours. This may 
seem simple, but many of these patients are extremely unreliable and 
occasionally uncooperative. Careful supervision of the patient is required 
to ensure that fasting does occur. Most of the ECT sessions are scheduled 
in the early morning to minimize the fasting period. 
Preanaesthetic medication with sedatives or narcotics is not 
required and may serve only to prolong the anaesthetic recovery time. 
Reassurance from the psychiatric staff should be sufficient to allay most 
of the patient’s fears regarding the upcoming treatment. 
 
 
 
 
 
 
 
 MONITORING AND CONDUCT OF ANAESTHESIA 
Intravenous access is secured.  
Monitoring includes pulse rate, arterial blood pressure, ECG and 
arterial oxygen saturation as a minimum. Full equipment to do 
Cardiopulmonary resuscitation (CPR) must be available. All the 
emergency drugs should be checked and kept ready. 
 The ideal intravenous anaesthetic agent would provide rapid onset 
short duration, attenuation of adverse physiological effects of ECT, rapid 
recovery and no adverse shortening of seizure duration.  The barbiturates 
like thiopentone sodium and methohexital have been used. Propofol, as 
an alternative IV induction drug is also preferred. 
 The use of neuromuscular blocking drugs has attenuate muscle 
contractions associated with ECT and essentially eliminated the risks of 
fractures or other injuries associated with muscle contractions.  
Succinycholine in the dose of 0.5 – 1 mg/kg has been used most often.  
The dosage should be modified on an individual basis. 
 Ventilation with an oxygen enriched mixture should be 
approximately assisted or controlled upto the time of the seizure and 
again following recovery from the seizure. 
 It is important to monitor patients closely immediately following 
ECT and during the recovery room until they have recovered from 
anaesthesia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PHARMACOLOGY OF PROPOFOL 
Propofol is a substituted Isopropyl phenol (2-6 – Disopropyl 
Phenol) 
It is an intravenous sedative and hypnotic 
 
 
 
 
 
 
Commercial Preparation : 
 10% soyabean oil, 1.2% purified egg phosphate, 2.25% glycerol 
Mechanism of Action : 
 Propofol is a selective modulator of GABA. GABA is an inhibitory 
neuro transmitter of the CNS. They increase transmembrane chloride 
conductance which result in hyperpolarisation of the postsynaptic cell 
membrane and functional inhibition of the post synaptic neuron. 
Pharmocokinetics : 
 Metobolism of propofol is extremely rapid. After 30 minutes less 
than 20% of IV bolus dose of propofol remain in the circulation as the 
 
 uncharged compound.  The drug is completely and rapidly metabolized to 
its sulphate and glucournide compounds and other related compounds 
that are eliminated via the kidney.  It is also been studied that the 
metabolism of drug is not markedly deranged in patients with moderate 
degree of renal and hepatic dysfunction.  Generally, clearance exceeds 
the capacity of liver blood supply suggesting that extrahepatic 
mechanisms constitute to the clearance of propofol from the blood. 
Effect on Organ systems : 
Cardiovascular system : 
 Propofol cause decrease in systemic blood pressure with 
corresponding decrease in cardiac output and systemic vascular 
resistance.   
 Negative ionotropic effect is due to decrease in intracellular 
calcium availability due to inhibition of sacrolemmal Ca++ shifts. 
Cardiac index remains unaltered.  
Respiratory systems : 
 Propofol produces dose dependent depression of ventilation and 
apnea may occur.  Propofol decreases the tidal volume and frequency of 
breathing.  The ventilatory response to hypercarbia and arterial 
hypoxemia are decreased by propofol. 
  It produce bronchodilatation and decreases the incidence of intra 
operative wheezing. Hypoxic pulmonary vasconstriction is intact. 
Hepatic and Renal function : 
 Propofol does not affect the hepatic or renal function.  Prolonged 
infusion of propofol may result in excretion of green urine and uric acid 
excretion is increased. 
Central Nervous System : 
 Propofol decreases the cerebral metabolic rate for oxygen 
(CMRO2), cerebral blood flow and ICP. It also decreases the systemic 
BP and hence decreases the cerebral perfusion pressure. 
 The effect of propofol on EEG activity is controversial.  It has 
direct anticonvulsant effect that is dose dependent.  Propofol also resulted 
in a shorter duration of motor and EEG activity after electro convulsive 
therapy. 
 Propofol also has neuroprotective effect – Propofol administered 
resulted in better burst suppression and better neurological outcome. 
Clinical Uses: 
Total Intravenous Anesthesia: Propofol has a short context sensitive 
half life and also has a short effect site equilibrium time thus making it a 
readily titratable drug for IV sedation. 
  The short context sensitive half life of propofol even with 
prolonged period of infusion combined with the short effect – site 
equilibrium time make this a readily titrable drug for IV sedation. 
Emergence from anaesthesia was rapid (time from end of infusion until 
patient being oriented was 12.8 – 18.9 min. In the recovery room patients 
were described as fully alert and oriented. 
Side effects: 
1.  Allergic reaction 
 Allergic component of propofol due to the phenyl nucleus and 
Disopropyl side chain 
2.  Bacterial growth: 
 Propofol supports the growth of Escherichia coli & Pseudomonas 
aeuroginosa – aseptic precaution during handling is a must. 
3.  Antioxidant property 
 Presence of phenolic group inhibits lipid peroxidation and 
scavengers free radicals. 
5.  Pain on Injection: 
 Pain on injection is more when the drug is injected into a smaller 
vein.  Using 1% lidocaine, short acting opioids and changing the 
composition of the carrier fat emulsion to long and medium chain 
triglycerides decrease the incidence of pain on injection. 
 PHARMACOLOGY OF THIOPENTONE SODIUM 
 Sodium 5 – ethyl – ( 1- methylbutyl) 2- thiobarbiturate 
 Invented in 1934 by Lundy and Waters 
 Derivatives of bartituric acid, formed by condensation of urea and 
malonic acid 
 Week acid – with pka above plasma pH making them largely 
unionised and hence able to cross the blood brain barrier. 
Dose of thiopental: 
 The dose of thiopental varies between 3 and 5 mg/kg, with an 
effective plasma concentration of 15mcg/mL. 
Pharmacodynamic effects: 
 Barbiturates are positive allosteric modulators at GABA and 
glycine receptors.  They cause increased channel opening time for 
chloride, which increase inhibitory effects. 
Pharmacokinetics: 
 The effect compartment equilibrium half-time for thiopentone is 
very short – 1.2 minutes, which is faster than for propofol. 
 Thiopentone is highly protein bound depending on pH. Binding 
falls as pH rise.  Clearance is by hepatic metabolism, not renal excretion 
 (<1%).  Plasma concentration falls rapidly after a bolus dose of 
thiopentone owing to uptake by vessel rich tissue.  
 Hepatic extraction ratio is low. It undergoes oxidation to the 
carboxylic acid derivative and to a lesser extent by S – Oxidation to 
Pentobarbital, a hypnotic oxybarbiturate will slow elimination. 
 After a single bolus dose or short infusion pharmacodynamic decay 
curves follow typical first order kinetics.  With longer, high-dose infusion 
hepatic metabolic capacity may be exceeded and zero-order kinetics may 
be seen.  Desulphuration may then become a significant metabolic 
pathway.  Recovery will be prolonged as a result of both reduced 
metabolism and the presence of an active metabolite. 
PHARMCODYNAMICS: 
Central Nervous System: 
 Central effects of thiopentone include sedation, anaethesia, 
anticonvulsion action, retrograde amnesia and depression of the 
vasomotor centre. 
 It is a cerebral vasoconstrictor causing a reduction in cerebral blood 
flow and intra cranial pressure and depression of cerebral metabolism.  
There are features of neuro protection.  Burst suppression of EEG can be 
induced with high doses. 
 Respiratory system : 
 Thiopentone causes centrally mediated respiratory depression and 
reduced sensitivity to raised CO2 which is dependent on dose and rate of 
injection.  Transient apnoea is common.  Laryngeal reflexes are intact. 
Coughing, laryngeal spasm and mild bronchoconstriction can occur 
particularly in asthmatics. 
Cardiovascular system : 
 Myocardial depressed in a dose dependent manner. Peripheral 
vascular resistance falls, leading to reduced preload and cardiac output.  
There is hypotension and tachycardia, which is exaggerated if there is 
hypovolemia, tight aortic stenosis and tamponade. 
Adverse Effects: 
1.  Respiratory depression, and airway obstruction. Laryngeal spasm is 
more common than with propofol.  Oxygen is administered by gentle 
manual IPPV via a mask.   
2. Circulatory collapse:  This is usually due to a relative overdose 
causing vasodilatation and myocardial depression.  It may also be due to 
anaphylaxis.  Treatment:  raise the legs; give oxygen by IPPV infuse 
fluids fast intravenously, administer inotropes. 
 3. Coughing: a sign of regurgitation, salivation or over-light 
anaesthesia.  Hiccup occasionally seen. 
4.  True cutaneous allergy can occur either in the form of a scarlatiniform 
rash or as true angioneurotic oedema.  Photosensitivity to thiopentone in 
patients recently exposed to sunlight has been reported. 
5.   Severe anaphylactic reactions (allergy).These reactions, although 
very rare, are dangerous.  They may take the form of cutaneous 
manifestations, (rashes, weals, flushes, oedema), cardiovascular collapse 
(hypotension, tachycardia), bronchospasm, laryngospasm and muscle 
rigidity or abdominal pain. 
6. Acute intermittent porphyria. Barbiturates may precipitate lower 
motor neuron paralysis and perhaps death in patients with porphyria and 
are absolutely contraindicated in them. 
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each patient receiving propofol or thiopentone.  The induction dose was 
1.6 mg / kg of propofol and 3mg/kg of thiopentone sodium.  The 
induction dose, rhythm and intraocular pressure were checked before 
induction and after administration of succinylcholine immediately, 5 
 minutes and 10 minutes after ECT administration. Recovery time was 
also compared between these two groups. 
Results:    Mean arterial pressure was lower following propofol than 
thiopentone (p<0.05) immediately after ECT.  Heart rate was lower 
following propofol than thipentone (p<0.05) immediately 5 minutes and 
10 minutes after ECT.  Intraocular pressure was lower following propofol 
than thiopentone (p<0.05) immediately 5 minutes and 10 minutes after 
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the middle cerebral artery during ECT by using propofol versus 
thiopentone Anaesthesia. 
 In the study, seizure duration was shorter in the propofol group.  
The shorter duration with the propofol and hence a smaller energy 
demand, may be a cause for the minor increase in cerebral blood flow 
velocity in the propofol group. The systemic haemodynamic changes are 
small and hence they cause a minor change in the cerebral 
haemodynamics compared to thiopentone group.  
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“Effect of Anaesthetic agent propofol on hormonal response to ECT”.  
Propofol is a new anaesthetic agent that reduces electroconvulsive 
therapy (ECT) seizure duration. They reviewed the endocrine response to 
ECT by two distinct mechanism, decreasing prolactin by reducing the 
seizure duration and decreasing ACTH and cortisal by another process, 
possibly via a reduction in central nor adrenergic activation. 
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 “Propofol Anesthesia in electroconvulsive therapy”  
“Reduced seizure duration may not be relevant” 
 In a prospective, randomized double blind study 20 subjects with 
major depressive illness received either propofol or methohexitone 
Anesthesia. The Hamilton depression rating scale was used to assess 
depression before therapy, at every third treatment and at the end of 
therapy.  Seizure duration was measured using the cuff technique. 
Results :  Mean seizure duration and mean total seizure duration were 
shorter in the propofol group but there was no difference in the outcome. 
Conclusion:  Use of propofol may not adversely affect outcome from 
depression and it is not necessarily contraindicated as an induction agent 
for ECT. 
 JOURNAL PAKISTAN MEDICAL ASSOCIATION FEB 2005 ; 50 
(2) 6:3  
“Comparison of thiopentone sodium and propofol for electro 
convulsive therapy.” 
Study conducted in department of anaesthesiology and intensive 
care, Aga khan University Hospital, Karachi. 
 Twenty five patients each undergoing atleast 2 sessions of ECT at 
the psychiatry department were included in the study.  Each patient either 
received thiopentone or propofol for induction of sleep in a randomized 
manner.  Drugs were evaluated regarding their effects on ECT induced 
haemodynamic changes (Blood Pressure, heart rate, seizure duration 
related to the procedure and recovery from sleep.  Any side effect during 
the procedure and recovery was also noted.  
They have concluded that propofol offered superior haemodynamic 
stability during the procedure and a quick recovery from sleep and 
propofol was found to be a better induction agent for ECT compared to 
thiopentone sodium. 
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 “Propofol reduces cognitive impairment after electro convulsive 
therapy”  
Cognitive impairment is the main complication after electro 
convulsive therapy (ECT). Modification of treatment parameters has been 
shown to affect the magnitude of these impairments, but the role of 
Anesthetic type remains unclear.  This study tested whether there is a 
difference in cognitive impairments immediately after ECT with propofol 
compared to thiopentone. 
 Method:  This was a randomized double blind cross over study which 
included 15 patients receiving right unilateral ECT for depression. Patient 
received propofol or thiopental on alternating ECT up to 6 treatments.  
Immediate and delayed verbal memory, reaction speed, and executive 
functions were assessed 45 minutes after each ECT. 
Result:   Cognitive impairment was reduced after ECT with propofol 
compared to thiopentone.  Time to emergence was quicker and EEG 
seizure duration shorter after propofol treatment.  There was no 
significant correlation between seizure duration and neuropsychological 
test performance. 
Gaines Gy, Rees DI, Anaesthetic Analog 1986 ; 65: 1345-56 
“Electroconvulsive therapy and Anaesthetic consideration.”   
 In this study, 85 patients who were undergoing ECT for major 
depression in ASA-I, II group were included in our study.  They used 
thiopentone, etomidote and propofol in succession in each patient.  The 
effect of these agents on motor and EEG seizure times, heart rate, mean 
BP and peripheral O2 saturation were compared.  They have concluded 
that Propofol appears to be a safe anaesthetic for ECT with minimal side 
effects.  It was found superior to thiopentone and etomidate in attenuating 
the physiological response to ECT with milder haemodynamic changes. 
  
AlRezah, Alinjanpour E.  Journal of Babol University of Medical 
Science in (JBUMS) 2005, 7 (3(27). 
“Comparison of Recovery duration of Propofol and thiopentone in ECT. 
 The aim of the study was compare the recovery duration of 
Propofol and thiopentone sodium in ECT. 
 Mean recovery duration of propofol and thipentone sodium was 
5.49+2.57 minutes and 6.4+3.69 minutes. They have concluded that 
propofol can prevent increasing haemodynamic response to ECT better 
than thiopentone sodium. 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
Study Design: 
Place & Period: 
  This study was done at the ECT treatment room in the 
Department of Psychiatry, Government Rajaji Hospital, Madurai attached 
to Madurai Medical College, Madurai from 2005 to 2007. 
Sample Size: 
 Sixty patients 
Inclusion Criteria : 
  Sixty patients (19-64 yrs) of ASA grade I and II patients 
diagnosed to have moderate to severe depression or mania in accordance 
with the international classification of disease 10th revision (ICD-10) who 
was prescribed ECT by the treating Psychiatrist were included in the 
study. 
Exclusion Criteria: 
 Patients with contraindication to ECT 
  Uncontrolled hypertension 
  Valvular heart diseases 
  Thyroid dysfunction 
  Allergy to sulfa drugs / egg protein 
  H/o Porphyria / Bronchial asthma 
  Those who were able to give written consent for ECT and 
anesthesia, written consent was obtained, and for those patients who were 
deemed unfit to give consent by the treating psychiatrist, consent was got 
from their relatives. 
Sampling Procedure: 
 The sixty patients in this study were randomly allocated into two 
groups, one of which received thiopentone sodium and the other propofol 
as the anesthetic agent for ECT. 
 Randomisation was done using a stratified design.  Patients were 
stratified according to whether they were diagnosed to have depression or 
mania.  Randomisation was done by the Psychiatric PG who 
subsequently did not have anything to do with treatment allocation or 
outcome assessment. 
 Outcome assessment was done by trained raters who were blind to 
the drug used.  Each patient’s pre-treatment and post-treatment 
psychiatric ratings were done by the same rater. 
 The Institution’s research and ethics committee approved the study. 
ECT was given thrice weekly on Tuesdays, Thursdays and Saturdays. 
 
 
 IMPLEMENTATION: 
  In all patients a detailed history, physical examination and 
relevant investigations were done and medication noted.  Patients who 
were on benzodiazepines had the drug discontinued 12 hours prior to 
ECT.  All patients were fasted overnight and received.   
Resuscitative equipments and emergency drugs were kept ready 
before administering ECT to treat the complications if any that might 
occur. 
1. Cylinders with full oxygen supply 
2. Laryngoscope with appropriate sized blades 
3. Endotracheal tubes of appropriate size and stylets 
4. Airway and mouth prop of appropriate sizes 
5. Functioning suction apparatus 
6. Vasopressors and drugs for resuscitation 
Intravenous access secured pre oxygenation was done.  Pulse rate and 
oxygen saturation was monitored continuously using a pulse oximeter.  
Preoperative B.P, HR and SPO2 were monitored and recorded. 
 After preoxygenation anesthesia was induced with either of the two 
drugs. Intravenous atropine sulfate 0.6mg was given. 
 a) Group A - Received propofol 1.5 mg / kg body weight with 1 ml 
of 2% Lignocaine hydrochloride as the anesthetic agent. Propofol 
was used for each subsequent ECT in these patients  
b)  Group – B:  Patients received Inj. Thiopentone sodium 2mg/kg 
body weight and continued to receive thiopentone sodium for each 
subsequent ECT. 
A blood pressure cuff was applied to the right upper arm and 
inflated to 40 mm of Hg above systolic B.P prior to the injection of 
succinylcholine to isolate the limb for monitoring motor seizure. 
In both the groups muscle relaxation was achieved with intravenous 
administration of 0.5 mg/kg / bd wt of succinycholine. 
Heart rate was monitored by manually palpating the radial artery 
pulsation and blood pressure was measured using blood pressure monitor 
at regular time intervals as indicated. 
A screen was put to separate the anaesthetist giving the drug and 
the anaesthetist who is performing the procedure and taking the reading. 
PROCEDURE:   
After establishing an I.V. line on the left forearm the calculated 
dose of propofol or thiopentone was given over a period of 20 seconds.  
The induction dose was considered adequate if the eyelash reflex was lost 
 after 30 seconds; otherwise additional agents were injected (with 
increments of 0.2 mg / kg body weight of propofol or 0.5 mg / kg body 
weight of thiopentone sodium) 
The sleep dose was recorded for subsequent treatment.  
Suxamethonium 0.5 mg/kg was given after the cuffed forearm was 
isolated. 
Patients were ventilated normally at the rate of 8-10 breaths / min 
with 100% O2.  Once the fasciculation due to suxamethonium subsided a 
soft mouth prop was inserted, bitemporal electrodes were placed for ECT 
and bilateral ECT was administered using brief pulse bidirectional 
constant current stimuli above seizure threshold (sine wave type) was 
used to administer electric shock. 
The duration of motor seizure was recorded by a stop watch as well 
as stimulus intensity and the number of re-stimulation required to achieve 
a motor seizure of atleast 15 seconds. Any patient who did not develop a 
bilateral tonic clonic motor seizure of atleast 15 seconds were 
restimulated with higher stimulus doses by increasing the duration of 
pulses until on adequate seizure was achieved and maximum of 3 
restimulations were permitted at each session. 
 Oxygenation was performed between re-stimulations. Once the 
motor seizure subsided patient’s ventilation was assisted with a facemask 
with 100% oxygen until the patient resumed spontaneous respiration. 
Any side effects like pain on injection, abnormal movement, and 
prolonged seizure defined as seizure duration > 120 sec, vomiting, 
bronchospasm or laryngospasm was noted. 
During recovery, after 30 minutes the patient was asked some 
simple questions which they were able to understand and comprehend to 
assess the patient’s orientation and ability to talk. Also the patient’s 
ability to walk to short distance unaided was assessed after 1 hour and 
graded by the recovery room nurse who remained blinded to the 
anesthetic agent given.  The presence of prolonged post-ictal restlessness 
or confusion was also noted. 
 
OUTCOME ASSESSMENTS  
Hamilton Depression Rating Scale (HDRS) was assessed pre and 
post treatment scores for depressed patients. Modified Mania Rating 
Scale (MMRS) was recorded pre and post treatment for mania patients by 
trained raters who remained blind to the anesthetic agent used.  
 
 Rating Scales : 
a) Hamilton Depression Rating Scale (HDRS): 
It is one of the best known depression rating scales which is used to 
rate the severity of symptoms.  It is a validated, internationally used 
assessment tool. It takes into account not only information from the 
patient but also from all other sources. The original version of the scale 
comprised of 21 items.  But this is reduced to 17 because the items of 
depersonalization / derealization, paranoia and obsessionality were found 
to be uncommon and diurnal variation was felt to be more related to the 
form of the illness.  Higher scores indicate more severe depressive 
symptom. A rating of less than 8 is usually taken to indicate the absence 
of significant depressive symptoms. 
b)  Modified Manic Rating Scale (MMRS) : 
This is a 28-item scale with ratings made on the basis of severity 
based on clinical interview and on information gained from relatives and 
nurses. It has satisfactory psychometric properties with good inter-rater 
reliability and test-retest reliability and is sensitive to change. 
Ratings were made in the mornings only to minimize the effects of 
diurnal variation of symptoms. The first rating was done within 48 hours 
 of the first. ECT treatment and the second was done within 2 weeks of 
the past ECT treatment. 
 The haemodynamic data was compared and analysed by the 
students‘t’ test.  A ‘p’ value of < 0.05 was considered statistically 
significant. 
Statistical Tools  
 The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002) 
developed by Centers for Disease Control and Prevention (CDC), Atlanta 
for W.H.O. 
 Using this software, frequencies, percentage, range, mean, standard 
deviation, x2 and 'p' values were calculated. A 'p' value less than 0.05 is 
taken to denote significant relationship. 
 
 
 
 
 
 
 
  
OBSERVATION & RESULTS 
 
 Sixty patients who underwent electroconvulsive therapy using 
propofol or thiopentone sodium as induction agents.  All of them were of 
either ASA class I or class II. 
     Table – 1 
Psychiatric Diagnosis of Patients in the two groups (n=60) 
ICD-10 Diagnosis Propofol Thiopentone Total 
Depression with psychosis 6 5 11 
Depression without psychosis 7 6 13 
Mania with psychosis 9 11 20 
Mania without psychosis 8 8 16 
Total 30 30 60 
 
Total 24(40%) patient were diagnosed to be depressives and 36 
(60%) were maniacs. 
 
 
 
  
 
 
DEMOGRAPHIC DATA 
Table - 2 
Demographical Data (n=60) 
Parameter Propofol Thiopentone Range P value 
Age (year) 
Mean + SD 
37.3 + 14.52 32.6 + 9.37 18-62 0.295 
Weight (kg) 
Mean + SD 
53.79 + 11.17 52.11 + 11.70 29-85 0.667 
Male  16 23   
Female  14 7   
 
 The mean age, weight and sex distribution of the included subjects 
are presented in Table 2  
Subjects in each group did not differ with respect to these variables. 
 
 
 
 
  
 
Patients in the two group did not differ with respect to proportions 
of patients who were previous drug non-responders. (Propofol 8/30, 
Thiopentone – 10/30) 
 Equal number of patients in each group was on concurrent 
medication, antidepressants or antipsychotics or both 
 The group did not significantly differ in proportion of patients with 
pre ECT physical risk factors such as hypertension (Propofol 4/30, 
Thiopentone 3/30) 
 Mean dose of Propofol given was 76.20 mg (SD + 14.76 mg) 
Range (60-100 mg). The mean dose of thiopentone given was 120 mg 
(SD + 28.30 range 100-200mg). The mean dose of succinylcholine given 
was 32.3 mg (SD + 6.57 mg) (range 20-50mg). 
 
 
 
 
 
 
  
 
HAEMODYNAMIC PARAMETERS 
Changes in heart rate before and after ECT (n=60) 
Table - 3 
Parameters 
 
Mean + SD ‘t’ test P value 
Thiopentone Propofol 
Pre 
ECT 
 90.30+9.38 90.50+8.36 0.44 0.903 
Not significant 
Post 
ECT 
1st min 95.88+8.80 94.28+9.5 0.50 0.676 
Not significant 
 2nd min 108.81+6.99 95.38+9.72 0.14 0.043 
significant 
 5th min 106.75+6.09 97.37+6.19 0.64 0.063 
Not significant 
 10th min 105.38+89.25 89.25+7.03 5.287 0.04 
Significant 
 
  
 
 
 
  
Heart Rate 
 The comparison of changes in the heart rate between the two 
groups is depicted in table 3. 
 There was an increase in heart rate from the second minute on 
wards in both groups. There was a maximum increase in heart rate by the 
5th minute in both groups, with the thiopentone group registering a higher 
heart rate than the propofol group.  The maximum differences in heart 
rate between the two groups were observed in the 10th minute. The mean 
heart rate in the propofol treated patients almost touched the pretreatment 
values, while the mean heart rate with the thiopentone group was still 
elevated.  
The difference in mean heart rate between the pre ECT and peak 
heart rate following ECT was 16.08 beats / min for thiopentone whereas 
it is 6.87 beats / min for propofol. 
In ECT there is an initial increase in parasympathetic stimulation 
between 0 to 2 minutes followed by sympathetic stimulation by 5 to 8 
minutes which is seen in my observation of the heart rate. 
  
 
  
 
 
Table - 4 
Changes in Systolic BP before and after ECT (n=60) 
Parameters 
 
Systolic Pressure  
Mean + SD
Mean 
differences 
‘t’ value Significance 
Thiopentone Propofol 
Pre 
ECT 
 127.63+11.97 125.33+10.68 0.55 0.5866 Not 
significant 
Post 
ECT 
1st min 139.77+13.07 128.77+14.85 2.220 0.0018 Significant 
 2nd min 154.1+24.5 138.9+23.1 2.570 0.0077 Significant 
 5th min 148.3+14.42 134.6+9.97 2.643 0.04 Significant 
 10th min 130.40+7.58 126.43+9.15 1.988 0.06 Not 
significant 
 
 
 
 
 
 
 Changes in Systolic BP before and after ECT 
 The comparison of systolic blood pressure pre induction and at 
various time intervals following delivery of ECT stimulus is shown in 
table 4 
 Baseline differences in B.P. between the two groups were not 
significant. 
 There was an increase in systolic BP following the administration 
of ECT in both groups, but the increase in systolic blood pressure is much 
higher with the thiopentone group compared to the propofol group. 
 There was maximum increase in BP at 2nd min in both the 
thiopentone and propofol group which is more with thiopentone 
compared to propofol and it is statistically significant. 
 There was an gradual increase in BP from the 2nd minute to 5th 
minute with a statistically significant increase in BP in the thiopentone 
group compared to the propofol group. 
 The systolic BP touched the baseline pressure at around the 10th 
min in both groups. 
 
 
 
  
 
 
Table - 5 
Changes in Diastolic blood pressure before and after ECT (n=60) 
 
Parameters 
 
Diastolic BP 
Mean + SD
‘t’ value P value 
Thiopentone Propofol 
Pre ECT  81.07+7.68 84.67+6.77 1.34 0.1849 
Not significant 
Post 
ECT 
1st min 98.1+11.45 90.27+9.3 2.03 0.0467 
Not significant 
 2nd min 92.43+7.63 83.47+6.75 3.36 0.0014 
Significant 
 5th min 86.47+6.74 81.4+6.81 2.01 0.0486 
Not significant 
 10th min 83.6+5.48 79.53+5.24 1.74 0.0866 
Not significant 
 
 
 
 
 
 
 
  
Changes in diastolic blood pressure before and after ECT 
The comparison of diastolic blood pressure pre induction and at 
various time intervals following administration of ECT is show in the 
chart. 
 Baseline values did not significantly differ in both the groups. 
 There was an increase in diastolic BP following the administration 
of ECT in both the groups with the increase in diastolic BP higher with 
the thiopentone group compared to the propofol group. 
 Diastolic BP touched the maximum level around 1-2 minutes.There 
was statistically significant increase in diastolic BP in the thiopentone 
group compared to the propofol group. 
 The diastolic BP started to decrease and reached the base line value 
by 8-10 minutes. 
 
 
 
 
 
 
 ECT TREATMENT DETAILS 
Table - 6 
Parameters 
 
Mean + SD ‘t’ test P value 
Thiopentone Propofol 
Mean seizure duration 
(sec) 
 Mean + SD 
41.79 + 11.73 29.59 +8.97 12.20 0.004 
Significant 
Max. stimulus 
Intensity (MS)  
Mean + SD 
165 + 55.59 276 + 90.99 4.08 0.0001 
Significant 
No.of patients who 
required restimulation 
5 (n=30) 9 (n=30) 0.8789 0.3831 
Not significant 
Total no.of ECT 
treatment 
6.47 + 1.57 7.37+1.52 1.57 0.1222 
Not significant 
 
Mean Seizure duration : 
 The mean seizure duration was more with thiopentone group 
compared to propofol group and it was statistically significant. Though 
propofol resulted in lesser mean seizure duration compared to the 
thiopentone group.  Use of propofol as an induction agent does not 
adversely affect the outcome from the illness as seen by the outcome 
scores (MMRS & DMRS Score).   
 Maximum stimulus intensity : (MS) 
 The maximum stimulus intensity that is required to produce seizure 
is recorded.  The observations showed that propofol group needed more 
stimulus intensity compared to the thiopentone group which was 
statistically significant. 
Restimulation : 
 Number of patients who required restimulations were more with the 
propofol group compared with the thiopentone group.  9/30 in propofol 
group and 5/30 in thiopentone group, but it was not found to be 
statistically significant. 
Total number of ECT treatments required  
 The total number of ECT treatments required to produce the desired 
effect is more with propofol group compared with the thiopentone group, 
but it was not statistically significant. 
 Thus, propofol use resulted in higher stimulus intensities being 
used to elicit adequate seizure, shorter seizure duration and greater 
number of treatments and more number of restimulations were required 
compared to the thiopentone group. 
 
 
  
 
 
 
Table - 7 
RECOVERY CHARACTERISTICS 
  Thiopentone Propofol 
a) Ability to talk after 30 min (Impaired) 16/30 6/30 
b) Ability to walk after  1 hour (Impaired) 13/30 4/30 
c) Post ECT complication   
 i)   Restlessness 
ii)  Post ictal confusion 
iii) Head ache 
iv) Nausea / vomiting / aspiration 
2 
4 
1 
1 
- 
- 
2 
1 
 
 
 
 
 
 
  
 
Recovery characteristics : 
 This chart compares the recovery characteristics of the two groups.  
The propofol group had early recovery and was able to talk and walk 
better at 20 minutes compared to the thiopentone group patients. 
 In the propofol group 6/30 patient had the impaired ability to talk 
after 30 minutes compared to 16/30 patients in thiopentone group. 
 The ability to walk unaided at 1 hour was impaired is 4/30 in 
propofol group compared to 13/30 in thiopentone group. 
 Post ECT complications were more in thiopentone group compared 
to propofol group. 
In thiopentone group, Restlessness (2)  Post ictal confusion (4) 
    Head ache (1)  Nausea / vomiting (1) 
In propofol group, Head ache (2)  Nausea (1) 
 
 
 
 
 
  
 
Table – 8 
Out come characteristics 
 Comparison of pre ECT and Post ECT Hamilton depression rating 
scale (HRDS) in depressive patients between two groups 
 
Parameters 
HDRS score 
Mean + SD 
 
‘t’ test 
 
P value Thiopentone Propofol 
Pre ECT 16.41+ 14.98 18.93+16.22 0.43 0.6652 
Not 
significant
Post ECT 4.17+4.59 5.07+4.56 0.59 0.5902 
Not 
significant
 
 Comparing the two groups showed that there is no difference in pre 
treatment scores in both groups.  Both groups were also similar in post 
treatment mean HDRS scores (statistically insignificant).  Thus there was 
no difference in outcome between the two groups. 
 
  
 
 
TABLE - 9 
Comparison of Pre and Post ECT Mania Rating Scale (MMRS)  
Score in Mania patients  
 
Parameters 
MMRS Score 
Mean + SD 
 
‘t’ test 
 
P value 
Thiopentone Propofol 
Pre ECT 46.40 +16.85 56.28+20.19 9.88 0.22 
Insignificant
Post ECT 10.60+13.81 14.42+21.52 3.82 0.2694 
Insignificant
 
 Analysis of the two groups revealed no differences in pre treatment 
scores in both groups. 
 There was no statistically significant difference between the 
MMRS score between propofol and thiopentone following ECT 
treatment. 
 
 
 DISCUSSION 
 
 This is a prospective study which compares Propofol with 
Thiopentone on haemodynamic parameters, seizure duration, recovery, 
complication and outcome in a mixed group of 60 depressed and maniac 
patients. 
 Both the groups were matched by demographic and clinical 
variables. Out of these 24 patients (40%) were diagnosed to be depressive 
and 36 patients (60%) were maniac patients. 
Pulse Rate : 
 Electroconvulsive therapy and the resultant seizures evokes an 
autonomic reaction generating a parasympathetic and then sympathetic 
activation sequence.  The phase of sympathetic activation and a 15 fold 
increase in circulating catecholamines results in severe tachycardia 
 Accordingly the maximum pulse rate registered in our study in a 
single patient was 159/minute from his basal pulse rate of 72 beats / 
minute. 
 There was an increase in mean heart rate from the second minute 
onwards for both thiopentone and propofol group with a maximum heart 
rate around the 5th minute. 
 Though initial tachycardia is due to the direct adrenergic outflow 
through sympathetic ganglia, the sustained response is due to the further 
release of epinephrine from adrenal medulla 
 The difference in mean heart rate between pre ECT heart rate and 
peak heart rate was 16.08 beats / min for thiopentone group, whereas it is 
6.87 beats/min for propofol. The finding of my study correlate with the 
studies of Boey WK Lai FO, (Anaesthesia analog 1990, Aug 45) who 
observed a statistically significant increase in heart rate in the thiopentone 
group compared to the propofol group.  Similar findings were observed 
by Park Hs et al, (BJA Oct 1999, 14:32) who observed that propofol had 
fewer effects on haemodynamic changes.   
 In our series, in which 2% of patients who were hypertensive, there 
was a very significant attenuation of pulse rate.  Thus, propofol use has a 
very significant protective effect on the cardiovascular system as a whole. 
Systolic and diastolic blood pressure 
 Both systolic and diastolic blood pressure   is observed to increase 
from 1-2 minutes post ECT. At 2 minutes post ECT, the increase in 
systolic blood pressure was 40% in the thiopentone group compared to 
9% in the propofol group. 
 In the 2nd, 5th & 10th min readings there was increase of BP more in 
the thiopentone group compared to the propofol group. 
 All these findings correlate well with the previous studies which 
showed a statistically significant difference in Blood pressure rise in 
thiopentone group compared to the Propofol group. 
 In 2% of patients who were hypertensives, systolic blood pressure 
reached basal levels at 2 minutes post ECT in the propofol group whereas 
they registered a 26% rise in the thiopentone group. 
 The observations made in systolic and diastolic BP in my study 
correlate well with the study of Kadoi Y Sait et al, (Anaesthesia Intensive 
care 2003 April 31(2), who observed decreased end systolic area (ESA) 
and decreased fractional area change (FAC) with the propofol group 
compared to the thiopentone group. Similar observation made by Boey 
WK, Lai Ko, Bonada et al, also confirmed the above findings with lesser 
increase in mean systolic and diastolic pressure in the propofol group 
compared to the thiopentone group. 
Mean Seizure Duration: 
There was statistically significant difference in mean seizure 
duration with the thiopentone group compared to the propofol group. 
  It is observed that propofol group needed more stimulus intensity 
compared to the thiopentone group which was statistically significant. 
 Though the total number of ECT treatments required to produce the 
desired effect is more with the propofol group compared with the 
thiopentone group, it was not statistically significant. 
 These findings of decrease in mean seizure duration in the propofol 
groups were comfirmed by the studies of Fear CF Little Johns CS, et al 
(BJA, 1995, March) who observed that reduced seizure duration in 
propofol group may not be relevant.  Similar observation was also made 
by Mitchell P. Smythe G. who observed a decrease in ACTH, prolactin 
and cortisol level in the propofol group compared to the thiopentone 
group which is due to the decreased mean seizure duration. 
Recovery characteristics: 
 The propofol group had early recovery and was able to talk at 30 
minutes and walk better at 1 hour compared to the thiopentone group. 
 Post ECT complications were more with the thiopentone group 
compared to the propofol group. 
 The earlier recovery with the propofol group compared to the 
thiopentone group were consistent with the findings of Butter Field NN et 
al (Journal of ECT March 2004; 20 (1)) who observed that propofol 
 would reduce cognitive impairment after electro convulsive therapy and 
hence earlier recovery characteristics.  Similar observations were made 
by Gracia et al (Rev Cub Med Mil Apr. June 2007) who observed a 
earlier recovery with propofol compared to the thiopentone group. 
Outcome Characteristics: 
 There was no statistically significant difference in Pre and Post 
ECT HDRS scores for depressive patients and pre and post ECT MMRS 
scores for maniac patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY 
 Modified electro convulsive therapy used to treat major affective 
disorders produces significant haemodynamic disturbances. 
Increase in heart rate and blood pressure can produce serious 
impact on the cardiovascular system and these would be more in 
hypertensives and these have to be attenuated.  Hypertension and 
tachycardia resulting from ECT may cause potentially serious adverse 
reactions such as myocardial infarction and stroke.  
 Sixty patients were randomized to receive either propofol (n=30) 
and thiopentone (n=30) in a prospective study to assess the 
haemodynamic changes, seizure characteristics, complications and 
psychological outcome. Out of 60 patients, 24 were (40%) depressive 
patients and 36(60%) were maniac patients in accordance with the ICD-
10 diagnostic guidelines, who underwent modified electroconvulsive 
therapy. Patients continued the prescribed medication and the number of 
ECT treatments were decided by the treating clinician based on clinical 
improvement. Heart rate and blood pressure were monitored before and 
at varying periods up to 10 minutes after each ECT treatment.  Induction 
and recovery times and post ECT complications were systematically 
observed. Clinical assessment of depression and mania were done by 
 trained raters who were blinded to the treatment assignment before the 
course of ECT and within two weeks of the last ECT treatment. 
The groups did not differ significantly on demographic and clinical 
variables before treatment.   
 The base line mean heart rate was 90.30/minute in the thiopentone 
group and 90.50/minute in the propofol group. 
 In the 2nd minute after ECT the mean heart rate was 108.81 (an 
increase of 18 beats) in the thiopentone group compare to 95.38 (an 
increase of 5 beats) in the propofol group which was statistically 
significant.  In the 5th minute, the mean heart rate was 106.75/minute in 
the thiopentone group compared to 97.37 / minute in the propofol group. 
By the 10th minutes, the mean heart rate continued to be higher in the 
thiopentone group (105.38/minute). while in the  propofol group the heart 
rate   touched the base line (89.25minute) which is also statistically 
significant. 
 On comparison of the systolic and diastolic BP the pre ECT mean 
systolic BP was 127.63 mmHg in the thiopentone group compared to 
125.33mmHg in the propofol group. The increase in BP in 1st minute was 
139.77mmHg the thiopentone group, compared to 128.77mmHg in the 
propofol group, which was statistically significant.  The mean systolic BP 
 was highest in the second minute was 154.1mmHg in the thiopentone 
group whereas in the propofol group it was 138.9mmHg. which is 
statistically significant. 
 Mean systolic pressure in the 5th minute was 148mmHg in the 
thiopentone group compared to 134 mmHg in the propofol group which 
is also statistically significant.  By the 10th minute, BP recorded was 
130.4mmHg in the thiopentone group while it was only 126.4mmHg in 
the propofol group. Thus BP almost touched the base line in the propofol 
group. 
 Patients with propofol group required higher mean stimulus 
intensity to elicit adequate seizures, which was 165ms in the thiopentone 
group compared to 276 ms in the propofol group.  Propofol group 
recorded a shorter mean duration of seizures 41.79seconds in the 
thiopentone group compared to 29.59seconds in the propofol group. 
 Propofol group also had more number of restimulation (5/30) in the 
thiopentone group compared to (9/30) in the propofol group. 
 Propofol group had early recovery characteristics compared to the 
thiopentone group. The ability to talk oriented at 30 minutes was 14 out 
of 30 patients in the thiopentone group compared to 24 out of 30 patients 
in the propofol group.  Similarly the ability to walk unaided at 1 hour was 
 17/30 patients in the thiopentone group whereas it is 26/30 patients in the 
propofol group. Thus, propofol group had early recovery characteristics 
compared to the thiopentone group and the post ECT complications were 
less with the propofol group.  
 Outcome of the study by evaluating the MMRS and HDRS score 
were similar in both thiopentone and propofol group. 
 The results of this study indicate that propofol is a safe induction 
agent for modified ECT with significant advantages over thiopentone 
with regard to haemodynamic changes, speed of induction and recovery 
from anaesthesia with little untoward complications associated with its 
use. While overall outcome was similar in patients treated with propofol 
and thiopentone, use of the former was associated with longer courses of 
treatment, shorter seizures and greater stimulus dosing used to ensure 
adequate seizures.  
These findings as well as the relatively higher cost of propofol 
indicates that the use of propofol as an induction agent for modified ECT 
should be reserved for those patients in whom it is required that 
elevations is heart rate and blood pressure after ECT are to be minimized.  
 
 Propofol would be ideal when early post operative recovery would 
be required as in day care surgeries with minimal post ECT 
complications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 Modified electroconvulsive therapy used to treat major affective 
disorders produces significant haemodynamic disturbances.  Tachycardia 
and hypertension due to sympathetic stimulation resulting from ECT may 
cause potentially serious side effects especially in patients with hypertensive 
heart disease, ischaemic heart disease and in patients with compromised 
cardiovascular function. 
 Propofol when used as an induction agent was associated with a lower 
increase in pulse rate and blood pressure, which would be advantages in 
patients in whom tachycardia and hypertension would be detrimental. 
 Routine use of propofol for ECT is not encouraged because use of 
propofol requires higher mean stimulus intensity to elicit adequate seizures, 
(276ms) shorter mean duration of seizure,(29.59sec) more restimulations 
(9/30) and more number of treatment compared to the thiopentone group and 
hence propofol may be the drug of choice for induction in patients in whom 
sudden haemodynamic changes following ECT are detrimental. 
Propofol use resulted in earlier recovery from the effects of anaesthesia 
than did the use of thiopentone.  This occurred in spite of the significantly 
greater stimulus dose used in propofol treated patients.  The use of propofol 
results in earlier recovery and less post ECT complications, which is of 
importance in the treatment of large numbers of outpatients. 
 
 HAMILTON DEPRESSION RATING SCALE (HDRS) 
1. DEPRESSED MOOD – Sadness, hopelessness, worthlessness 
 0) Absent 
 1) These feeling states indicated only on questioning 
 2) These feeling states spontaneously reported verbally 
 3) Communicates feeling states non-verbally (i.e. through facial expression, posture, 
voice and tendency to weep) 
 4) Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal 
and non-verbal communication. 
2. FEELING OF GUILT 
 0) Absent 
 1) Self reproach, feels he has let people down 
 2) Ideas of guilt or rumination over past errors or sinful deeds 
 3) Present illness is a punishment.  Delusions of guilt 
 4) Hears accusatory or denunciatory voices and / or experiences threatening visual 
hallucinations. 
3. SUICIDE 
 0) Absent 
 1) Feels like life is not worth living 
 2) Wishes he were dead or any thoughts of possible death to self 
 3) Suicide ideas or gesture 
 4) Attempts at suicide (any serious attempts rates 4) 
4. INSOMNIA EARLY 
 0) No difficulty 
 1) Complains of occasional difficulty falling asleep (ie. More  
  than ½ hour) 
 2) Complains of nightly difficulty falling asleep 
 
5.  INSOMNIA MIDDLE 
 0) No difficulty 
 1) Patient complains of being restless and disturbed during the night 
 2) waking during the night (any getting out of bed rates 2,except for the purpose of 
 voiding) 
6. INSOMNIA LATE 
 0)   No difficulty 
 1) Waking in early hours of the morning but goes back to sleep 
 2) Unable to fall asleep again if gets out of bed 
7.  WORK ANDACTIVITIES 
 0) No difficulty 
 1) Thoughts and feelings of incapacity, fatigue or weakness related to activities, work 
or bobbies 
 2) Loss of interest in activity, hobbies or work – directly reported by patient or indirect 
in listlessness, indecision and cacillation (feels he has to push self to work or join activities) 
 3) Decrease in actual time spent in activities or decrease in productivity (in hospital, 
rate 3 if patient does not spend atleast three hours a day in activities, hospital job or hobbies, 
exclusive of ward chores.) 
 4) Stopped working because of present illness (in hospital, rate 4 if patient engages in 
no activities except ward chores, or if patient fails to perform ward chores unassisted. 
 
8. RETARDATION  -   Slowness of thought  and speech impaired ability to concentrate 
decreased motor activity 
 0) Normal speech and thought 
 1) Slight retardation at interview 
 2) Obvious retardation at interview 
 3) Interview difficult 
  4) Complete stupor 
9. AGITATION 
 0) None 
 1) Fidgetiness 
 2) Playing with hands, hair etc 
 3) Moving about, can’t sit still 
 4) Hand wringing, nail biting, hair-pulling, biting of lips 
10.  ANXIETY PSYCHIC 
 0) No difficulty 
 1) Subjective tension and irritability 
 2) Worrying about minor matters 
 3) Apprehensive attitude apparent in face or speech 
 4) Fears expressed without questioning 
11.  ANXIETY SOMATIC – Physiological concomitants of anxiety such as : 
 Gastrointestinal (dry-mouth, wind,indigestion, diarrhea, cramps, belching) 
 Cardiovascular (palpitation, headaches) 
 Respiratory (hyperventilation, sighing) 
 Urinary frequency 
Sweating 
0) Absent 
1) Mild 
2) Moderate 
3) Severe 
4) Incapacitating 
12. SOMATIC SYMPTOMS, GASTRO INTESTINAL 
 0) None 
 1) Loss of appetite but eating without staff encouragement.  Heavy feelings in 
abdomen 
 2) Difficulty eating without staff urging. Requests or requires laxatives or medication 
for bowels or medication for G.I. symptoms. 
13. SOMATIC SYMPTOMS, GENERAL 
 0) None  
 1) Heaviness in limbs,back or head, backaches, headaches, muscle aches, Loss of 
energy and fatigability 
 2) Any clear-cut symptom rates 2 
 
14. GENITAL SYMPTOMS – Loss of libido, menstrual disturbances  
 0) Absent 
 1) Mild 
 2) Severe 
15. HYPOCHONDRIASIS 
 0) Not present 
 1) Self-absorption (bodily) 
 2) Pre occupation with health 
 3) Frequent complaints, requests for help etc, 
 4) Hypochondriacal delusions 
16. LOSS OF WEIGHT – RATING BY HISTORY 
 0) No weight loss 
 1) Probable weight loss associated with present illness 
 2) Definite weight loss (according to patient) 
17. INSIGHT 
 0) Acknowledges being depressed and ill 
 1) Acknowledges illness but attributes cause to bad food, 
 climate, overwork, virus, need for rest, etc. 
 2) Denies being ill at all 
  
MODIFIED MANIC STATE RATING SCALE (MMRS) 
 0 = Absent 
 1 = Slight flavor or suspicion of pathology by clinician 
 2 = Clearly noticeable but mild or occurring not more than  
   twice during interview 
 3 = Clearly present and occurring 3-4 times during  
   interview 
 4 = Definitely present and frequent 
 5 = Continuous and gross 
1. Is depressed 
2. Is talking excessively 
3. Restlessness 
4. Make threats 
5. Has poor judgement 
6. Is hallucinating 
7. Looks happy and cheerful 
8. Seeks out others 
9. Is distractable 
10. Has grandiose ideas 
11. Has grandiose delusions 
12. Is angry 
13. Is suspicious 
14. Has delusions of persecution 
15. Is active 
16. Is irritable 
17. Jumps from one topic to another 
18. Shows flight of ideas 
19. Is careless about dress and grooming 
20. Has diminished impulse control 
21. Verbalizes feelings of well-being 
22. Makes plans 
23. Demands contact 
24. Is sexually pre-occupied 
25. Is emotionally labile 
26. Is religious 
27. Is disinhibited 
28. Has disturbed sleep 
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 PROFORMA 
Name Age Sex Weight Height Hospital No. 
      
 
ICD-10 Diagnosis : 
Indication for ECT : (Tick Appropriate) 
a) High Suicidal risk 
b) Drug non-response 
c) Intolerance to Drug 
d) To hasten recovery 
e) Response only to ECT in previous episodes 
f) Others 
Current Drug Therapy : 
Fasting Period : 
Pre-Medication: Inj. Atropine 0.6 mg – (YN) 
Induction Drug Given:  Thiopentone / Propofol (with Dosage) 
Inj. Succinylcholine : Dose 
Induction Time   
Stimulation Intensity   
Seizure Duration   
No.of Restimulation   
 
Para 
meter 
Pre ECT Post ECT 
  1st min 2nd min 5th min 10th min 30th min 
HR             
Systole 
BP 
Diastole 
            
 
 
 
 Other features:  (v) Hicoughs / Branchospasms / Cough 
Recovery Features 
No. Action Time Ability 
1. Opening of eyes   
2. Ability to obey vocal commands   
3. Sit up unaided   
4. Ability to walk  Impaired / unimpaired 
5. Ability to talk  Impaired/ unimpaired 
 
Post ECT Complications: (Tick Appropriately) 
 Restlessness / post Ictal confusion / Head ache / Nausea / vomiting / 
Aspiration 
 
Patient Outcome: 
 HDRS YMRS 
Pre ECT   
Post ECT   
 
 
                 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
MASTER CHART ABBREVIATIONS 
 
 
 HR  - HEART RATE 
  
 SP  - SYSTOLIC BLOOD PRESSURE 
  
 DP  - DIASTOLIC BLOOD PRESSURE 
 
 HDRS - HAMILTON DEPRESSION RATING SCALE 
 
 MMRS - MODIFIED MANIA RATING SCALE 
  
 IMP  - IMPAIRED 
 
 UNIMP - UNIMPAIRED 
 
 N  - NO 
 
 Y  - YES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
